Bionomics Limited (NASDAQ:BNOX) shares traded 20.28% higher at $4.33 on Wall Street last session.
BNOX stock price is now 2.22% away from the 50-day moving average and -43.58% away from the 200-day moving average. The market capitalization of the company currently stands at $36.80M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
With the price target of $54, H.C. Wainwright recently initiated with Buy rating for Bionomics Limited (NASDAQ: BNOX). On January 10, 2022, Evercore ISI recently initiated its ‘Outperform’ rating on the stock quoting a target price of $17, while ‘Cantor Fitzgerald’ rates the stock as ‘Overweight’.
There have been several recent changes in the stakes of large investors in BNOX stock. A new stake in Bionomics Limited shares was purchased by POINT72 ASSET MANAGEMENT, L.P. during the first quarter worth $461,000. In total, there are 6 active investors with 7.81% ownership of the company’s stock.
Bionomics Limited (NASDAQ: BNOX) opened at $3.3100 on Tuesday. During the past 12 months, Bionomics Limited has had a low of $2.49 and a high of $10.90. The fifty day moving average price for BNOX is $4.0168 and a two-hundred day moving average price translates $6.5521 for the stock.
The latest earnings results from Bionomics Limited (NASDAQ: BNOX) was released for Jun, 2022. For the current quarter, analysts expect BNOX to generate $280k in revenue.
Bionomics Limited(BNOX) Company Profile
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company’s lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
